Search the Newsreel

Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A

Armistice Capital and Steven Boyd have filed an amended Schedule 13G disclosing a 1.67% beneficial ownership stake in Travere Therapeutics (TVTX). This ownership translates to 1,572,539 shares of common stock, with shared voting and dispositive power, falling below the 5% reporting threshold for a …

Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net Loss - Has The Bull Case Changed?

Travere Therapeutics reported strong Q2 2026 revenue of US$169.58 million, a significant increase from the previous year, but also a wider net loss of US$34.8 million. The article discusses how this revenue growth, driven by its drug FILSPARI, reinforces the company's investment narrative focused …

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …

Tapestry Sank 15% Despite a Q4 Earnings Beat. The FY27 Guide Is Why.

Tapestry's stock fell 15% despite beating Q4 earnings expectations, primarily due to its conservative FY27 guidance. While the company exceeded its Investor Day targets two years early with strong Q4 performance, especially from Coach in China and Europe, the projected mid-single-digit revenue growth and …

Dianthus Therapeutics stock hits 52-week high at 114.64 USD

Dianthus Therapeutics Inc. (DNTH) stock has reached a new 52-week high of $114.64, trading at $114.68, marking a 441% increase over the past year and 166% year-to-date. This surge follows recent positive developments, including the announcement of second-quarter 2026 earnings, the introduction of a …

Suzano S.A. 2026 Q2 - Results - Earnings Call Presentation (NYSE:SUZ) 2026-08-13

This article presents the slide deck published by Suzano S.A. for its Q2 2026 earnings call, held on August 13, 2026. The content is provided by SA Transcripts, which specializes in earnings call documentation. It serves as a resource for investors interested in Suzano …

Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals. The combined company is advancing a portfolio of clinical-stage therapies …

Medicenna Therapeutics Corp. Reports Earnings Results for the First Quarter Ended June 30, 2026

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

PTCT Maintained by Barclays -- Price Target Raised to $122

Barclays has maintained an "Overweight" rating for PTC Therapeutics (PTCT) and increased its price target to $122.00 from $120.00. Despite this positive analyst outlook, GuruFocus indicates the stock is significantly overvalued at $71.52 against a GF Value of $37.55, with a mixed GF Score …

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has reported a beneficial ownership of 9.96% in CytomX Therapeutics (CTMX). This group collectively holds shared voting and dispositive power over 21,703,093 shares of common stock. The disclosure was made …

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a …

Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is …

Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7% - Here's Why

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis

Fate Therapeutics has started RECLAIM-LN, a Phase 2 registrational trial for its off-the-shelf CAR T-cell therapy FT819, targeting refractory lupus nephritis. This follows positive Phase 1 safety and efficacy data. The trial, developed with FDA interaction, aims to enroll 53 patients, with preliminary data …

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%

Short interest in Indaptus Therapeutics (NASDAQ:INDP) dramatically decreased by 64.1% in July, totaling 93,141 shares as of July 31st. Despite beating consensus EPS estimates for the quarter, the stock trades near its one-year low, and analyst sentiment remains negative with an average "Sell" rating. …

Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund

Denali Therapeutics Inc. CEO, Ryan J. Watts, donated 32,220 shares of common stock to a donor-advised fund on August 12, 2026, as disclosed in an SEC Form 4 filing. This charitable gift, valued at $0, was reported on August 14, 2026. Following the donation, …

Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook

Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary

Jasper Therapeutics, Inc. reported a significant reduction in its net loss for the second quarter of 2026, posting $(2.8M) compared to $(26.7M) in the prior year, with diluted EPS improving to $(0.10) from $(1.74). The company, which remains pre-revenue, highlighted strategic repositioning through the …

Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M

Jasper Therapeutics (JSPR) significantly reduced its net loss in the first half of 2026 to $3.9 million from $48.0 million the previous year, primarily due to lower operating expenses and non-cash adjustments. Subsequent to the quarter, the company acquired Kira Pharmaceuticals, adding new complement-pathway …

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics announced its second quarter 2026 financial results, highlighted by the acquisition of Kira Pharmaceuticals and a successful $132 million PIPE financing. The combined company now possesses a strengthened portfolio of clinical-stage assets for immune-mediated diseases, including KP-104, briquilimab, and KP-701, with sufficient …

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

Notable ETF Outflow Detected - SPSM, CORT, GKOS, EAT

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 600 Small Cap ETF (Symbol: SPSM) where we have detected an approximate $125.1 million dollar outflow -- that's a 0.7% decrease …

JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total …

Tapestry's Coach International Growth Could Offset North America Slowdown, Morgan Stanley Says

Tapestry's (TPR) fiscal Q4 results showed a slowdown in Coach's North American business, but stronger international growth could support the company's growth trajectory, Morgan Stanley said.Coach North America growth slowed to 10% year over year in Q4, while international sales Silver Upgrade to read …

Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate

Quince Therapeutics (NASDAQ: QNCX) significantly beat Q2 2026 EPS estimates with a loss of $(12.31) against a consensus of $(26.32), marking an 81.9% improvement year-over-year. The company completed its acquisition of Orphai Therapeutics and raised $115 million in a private placement, strengthening its cash …

Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position

Woodline Partners LP has reported an 8.1% beneficial ownership stake in Zevra Therapeutics, Inc. (ZVRA), amounting to 4,785,771 shares. This disclosure, made via an amended Schedule 13G, indicates that Woodline Partners has sole voting and dispositive power over these shares. The ownership percentage is …

Bernstein raises Tapestry stock price target to $185 on Coach growth

Bernstein SocGen Group has increased its price target for Tapestry Inc. (NYSE:TPR) to $185, citing the strong growth of its Coach brand. This adjustment comes amidst Tapestry's impressive financial performance, including 14% revenue growth and a 78% gross profit margin, with analysts noting the …

Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss

Candel Therapeutics (NASDAQ:CADL) stock fell 4.6% after reporting a quarterly loss of $0.52 per share, missing the consensus estimate of $0.27. Despite the earnings miss, management highlighted progress towards a biologics license application submission in Q4 and a first commercial product target for 2027. …

Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G/A, reporting a beneficial ownership of 3,436,000 shares of Voyager Therapeutics, Inc. (VYGR) common stock, which represents 5.58% of the class. They hold shared voting and dispositive power over these shares, which are directly …

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)